{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:26:45Z","timestamp":1784028405464,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Special Research Fund for Hospital Pharmacy of Shandong Pharmaceutical Association","award":["yyyx2021qn-04"],"award-info":[{"award-number":["yyyx2021qn-04"]}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020QH361"],"award-info":[{"award-number":["ZR2020QH361"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00965-5","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T05:36:29Z","timestamp":1752816989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug-induced sinusoidal obstruction syndrome: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System (FEARS)"],"prefix":"10.1186","volume":"26","author":[{"given":"Cuicui","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"4","key":"965_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","volume":"4","author":"CQ Fan","year":"2014","unstructured":"Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2014;4(4):332\u201346. https:\/\/doi.org\/10.1016\/j.jceh.2014.10.002.","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"965_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clinre.2020.03.019","volume":"44","author":"V de L\u00e9dinghen","year":"2020","unstructured":"de L\u00e9dinghen V, Villate A, Robin M, Decraecker M, Valla D, Hillaire S, et al. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2020;44(4):480\u20135. https:\/\/doi.org\/10.1016\/j.clinre.2020.03.019.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"965_CR3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transpl. 2016;51(7):906\u201312. https:\/\/doi.org\/10.1038\/bmt.2016.130.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"965_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16(2):157\u201368. https:\/\/doi.org\/10.1016\/j.bbmt.2009.08.024.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"965_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"J-H Dalle","year":"2016","unstructured":"Dalle J-H, Sergio A, Giralt. Hepatic Veno-Occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl. 2016;22(3):400\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.024.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"965_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","volume":"26","author":"M Hauben","year":"2003","unstructured":"Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26(3):159\u201386. https:\/\/doi.org\/10.2165\/00002018-200326030-00003.","journal-title":"Drug Saf"},{"issue":"7","key":"965_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"issue":"2","key":"965_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"HJ Duggirala","year":"2016","unstructured":"Duggirala HJ, Tonning JM, Smith E, Bright RA, Baker JD, Ball R, et al. Use of data mining at the food and drug administration. J Am Med Inf Assoc. 2016;23(2):428\u201334. https:\/\/doi.org\/10.1093\/jamia\/ocv063.","journal-title":"J Am Med Inf Assoc"},{"key":"965_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","volume":"134","author":"C Khouri","year":"2021","unstructured":"Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol. 2021;134:14\u201321. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.01.015.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"965_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","volume":"30","author":"R B\u00f6hm","year":"2012","unstructured":"B\u00f6hm R, H\u00f6cker J, Cascorbi I, Herdegen T. OpenVigil\u2013free eyeballs on AERS pharmacovigilance data. Nat Biotechnol. 2012;30(2):137\u20138. https:\/\/doi.org\/10.1038\/nbt.2113.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"965_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00702-020-02276-x","volume":"128","author":"S Greten","year":"2021","unstructured":"Greten S, M\u00fcller-Funogea JI, Wegner F, H\u00f6glinger GU, Simon N, Junius-Walker U, et al. Drug safety profiles in geriatric patients with parkinson\u2019s disease using the FORTA (Fit fOR the Aged) classification: results from a mono-centric retrospective analysis. J Neural Transm (Vienna). 2021;128(1):49\u201360. https:\/\/doi.org\/10.1007\/s00702-020-02276-x.","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"965_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hep.26175","volume":"57","author":"JH Hoofnagle","year":"2013","unstructured":"Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. Hepatology. 2013;57(3):873\u20134. https:\/\/doi.org\/10.1002\/hep.26175.","journal-title":"Hepatology"},{"issue":"6","key":"965_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transpl. 2015;50(6):781\u20139. https:\/\/doi.org\/10.1038\/bmt.2015.52.","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"965_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/imj.13550","volume":"47","author":"A Piccin","year":"2017","unstructured":"Piccin A, Sartori MT, Bisogno G, Van Schilfgaarde M, Saggiorato G, Pierro AMD, et al. New insights into sinusoidal obstruction syndrome. Intern Med J. 2017;47(10):1173\u201383. https:\/\/doi.org\/10.1111\/imj.13550.","journal-title":"Intern Med J"},{"issue":"4","key":"965_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/10245332.1998.11746403","volume":"3","author":"E Carreras","year":"1998","unstructured":"Carreras E, Rozman C. The syndrome of Veno-occlusive disease after blood or marrow transplantation. Hematology. 1998;3(4):303\u201314. https:\/\/doi.org\/10.1080\/10245332.1998.11746403.","journal-title":"Hematology"},{"issue":"5","key":"965_CR16","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior Gemtuzumab Ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578\u201382. https:\/\/doi.org\/10.1182\/blood-2003-01-0255.","journal-title":"Blood"},{"issue":"4","key":"965_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"15","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;15(4):255\u201367. https:\/\/doi.org\/10.7326\/0003-4819-118-4-199302150-00003.","journal-title":"Ann Intern Med"},{"issue":"10","key":"965_CR18","first-page":"1396","volume":"90","author":"S Cesaro","year":"2005","unstructured":"Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica. 2005;90(10):1396\u2013404.","journal-title":"Haematologica"},{"issue":"12","key":"965_CR19","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","volume":"92","author":"H H\u00e4gglund","year":"1998","unstructured":"H\u00e4gglund H, Remberger M, Klaesson S, L\u00f6nnqvist B, Ljungman P, Ringd\u00e9n O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood. 1998;92(12):4568\u201372.","journal-title":"Blood"},{"issue":"4","key":"965_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, et al. BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following Haematopoietic stem cell transplantation. Br J Haematol. 2013;163(4):444\u201357. https:\/\/doi.org\/10.1111\/bjh.12558.","journal-title":"Br J Haematol"},{"issue":"9","key":"965_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/s0959-8049(01)00097-1","volume":"37","author":"L D\u2019Antiga","year":"2001","unstructured":"D\u2019Antiga L, Baker A, Pritchard J, Pryor D, Mieli-Vergani G. Veno-occlusive disease with multi-organ involvement following actinomycin-D. Eur J Cancer. 2001;37(9):1141\u20138. https:\/\/doi.org\/10.1016\/s0959-8049(01)00097-1.","journal-title":"Eur J Cancer"},{"issue":"10","key":"965_CR22","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1200\/JCO.2004.08.075","volume":"22","author":"C Arndt","year":"2004","unstructured":"Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol. 2004;22(10):1894\u2013901. https:\/\/doi.org\/10.1200\/JCO.2004.08.075.","journal-title":"J Clin Oncol"},{"issue":"8","key":"965_CR23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/08880010701640390","volume":"24","author":"E Cecen","year":"2007","unstructured":"Cecen E, Uysal KM, Ozguven A, Gunes D, Irken G, Olgun N. Veno-occlusive disease in a child with rhabdomyosarcoma after conventional chemotherapy: report of a case and review of the literature. Pediatr Hematol Oncol. 2007;24(8):615\u201321. https:\/\/doi.org\/10.1080\/08880010701640390.","journal-title":"Pediatr Hematol Oncol"},{"issue":"4","key":"965_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1875-9572(08)60029-7","volume":"49","author":"IL Chen","year":"2008","unstructured":"Chen IL, Yang SN, Hsiao CC, Wu KS, Sheen JM. Treatment with high-dose Methylprednisolone for hepatic veno-occlusive disease in a child with rhabdomyosarcoma. Pediatr Neonatol. 2008;49(4):141\u20134. https:\/\/doi.org\/10.1016\/S1875-9572(08)60029-7.","journal-title":"Pediatr Neonatol"},{"issue":"5","key":"965_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/mpo.2950240513","volume":"24","author":"VS Kanwar","year":"1995","unstructured":"Kanwar VS, Albuquerque ML, Ribeiro RC, Kauffman WM, Furman WL. Veno-occlusive disease of the liver after chemotherapy for rhabdomyosarcoma: case report with a review of the literature. Med Pediatr Oncol. 1995;24(5):334\u201340. https:\/\/doi.org\/10.1002\/mpo.2950240513.","journal-title":"Med Pediatr Oncol"},{"issue":"12","key":"965_CR26","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/(sici)1097-0142(19970615)79:12<2435::aid-cncr21>3.0.co;2-r","volume":"79","author":"JA Ortega","year":"1997","unstructured":"Ortega JA, Donaldson SS, Ivy SP, Pappo A, Maurer HM. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the intergroup rhabdomyosarcoma study group. Childrens Cancer group. the pediatric oncology group. and the pediatric intergroup statistical center. Cancer. 1997;79(12):2435\u20139. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19970615)79:12%3C2435::aid-cncr21%3E3.0.co;2-r.","journal-title":"Cancer"},{"issue":"12","key":"965_CR27","first-page":"843","volume":"26","author":"ML Sulis","year":"2004","unstructured":"Sulis ML, Bessmertny O, Granowetter L, Weiner M, Kelly KM. Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma. J Pediatr Hematol Oncol. 2004;26(12):843\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"965_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic Veno-Occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl. 2016;22(3):400\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.024.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"965_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbmt.2018.09.027","volume":"25","author":"M Faraci","year":"2019","unstructured":"Faraci M, Bertaina A, Luksch R, Calore E, Lanino E, Saglio F, et al. Sinusoidal obstruction Syndrome\/Veno-Occlusive disease after autologous or allogeneic hematopoietic stem cell transplantation in children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic stem cell transplantation group. Biol Blood Marrow Transpl. 2019;25(2):313\u201320. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.027.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"965_CR30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clinre.2016.01.006","volume":"40","author":"DC Valla","year":"2016","unstructured":"Valla DC, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2016;40(4):378\u201385. https:\/\/doi.org\/10.1016\/j.clinre.2016.01.006. Epub 2016 Mar 30.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"965_CR31","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.3892\/mmr.2017.6407","volume":"15","author":"M Hirata","year":"2017","unstructured":"Hirata M, Tajima H, Miyashita T, Miyata T, Nakanuma S, Makino I, et al. Extravasated platelet aggregation in the livers of rats with drug-induced hepatic sinusoidal obstruction syndrome. Mol Med Rep. 2017;15(5):3147\u201352. https:\/\/doi.org\/10.3892\/mmr.2017.6407.","journal-title":"Mol Med Rep"},{"issue":"5","key":"965_CR32","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/SLA.0b013e3182a6183e","volume":"258","author":"CL Vigan\u00f2L","year":"2013","unstructured":"Vigan\u00f2L CL, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258(5):731\u201340. https:\/\/doi.org\/10.1097\/SLA.0b013e3182a6183e.","journal-title":"Ann Surg"},{"key":"965_CR33","doi-asserted-by":"publisher","first-page":"314868","DOI":"10.1155\/2013\/314868","volume":"2013","author":"E Nguyen-Khac","year":"2013","unstructured":"Nguyen-Khac E, Lobry C, Chatelain D, Fuks D, Joly JP, Brevet M, et al. A reappraisal of Chemotherapy-Induced liver injury in colorectal liver metastases before the era of antiangiogenics. Int J Hepatol. 2013;2013:314868. https:\/\/doi.org\/10.1155\/2013\/314868.","journal-title":"Int J Hepatol"},{"issue":"11","key":"965_CR34","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/hpb.12047","volume":"15","author":"C Hubert","year":"2013","unstructured":"Hubert C, Sempoux C, van den Humblet Y, Zech F, Leclercq I, et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford). 2013;15(11):858\u201364. https:\/\/doi.org\/10.1111\/hpb.12047.","journal-title":"HPB (Oxford)"},{"issue":"2","key":"965_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jhep.2013.04.014","volume":"59","author":"SM Robinson","year":"2013","unstructured":"Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol. 2013;59(2):318\u201326. https:\/\/doi.org\/10.1016\/j.jhep.2013.04.014.","journal-title":"J Hepatol"},{"issue":"5","key":"965_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/s-2008-1072380","volume":"10","author":"P Czauderna","year":"2000","unstructured":"Czauderna P, Katski K, Kowalczyk J, Kurylak A, Lopatka B, Skotnicka-Klonowicz G, et al. Venoocclusive liver disease (VOD) as a complication of wilms\u2019 tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg. 2000;10(5):300\u20133. https:\/\/doi.org\/10.1055\/s-2008-1072380.","journal-title":"Eur J Pediatr Surg"},{"issue":"9544","key":"965_CR37","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(06)69558-5","volume":"368","author":"A Vora","year":"2006","unstructured":"Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 2006;368(9544):1339\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(06)69558-5.","journal-title":"Lancet"},{"issue":"14","key":"965_CR38","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/blood-2009-07-230656","volume":"115","author":"LC Stork","year":"2010","unstructured":"Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the children\u2019s oncology group CCG-1952 clinical trial. Blood. 2010;115(14):2740\u20138. https:\/\/doi.org\/10.1182\/blood-2009-07-230656.","journal-title":"Blood"},{"key":"965_CR39","doi-asserted-by":"publisher","unstructured":"Toksvang LN, De Pietri S, Nielsen SN, Nersting J, Albertsen BK, Wehner PS, et al. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites. Pediatr Blood Cancer. 2017;64(9). https:\/\/doi.org\/10.1002\/pbc.26519.","DOI":"10.1002\/pbc.26519"},{"issue":"3","key":"965_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clml.2012.12.003","volume":"13","author":"P Kebriaei","year":"2013","unstructured":"Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13(3):296\u2013301. https:\/\/doi.org\/10.1016\/j.clml.2012.12.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"965_CR41","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.bbmt.2016.04.011","volume":"22","author":"C Strouse","year":"2016","unstructured":"Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, et al. Defibrotide for treatment of severe Veno-Occlusive disease in pediatrics and adults: an exploratory analysis using data from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2016;22(7):1306\u201312. https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.011.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"965_CR42","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277.","journal-title":"N Engl J Med"},{"issue":"4","key":"965_CR43","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s12185-013-1275-2","volume":"97","author":"MS Tallman","year":"2013","unstructured":"Tallman MS, McDonald GB, DeLeve LD, Baer MR, Cook MN, Graepel GJ, et al. Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice. Int J Hematol. 2013;97(4):456\u201364.","journal-title":"Int J Hematol"},{"issue":"4","key":"965_CR44","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clinre.2016.01.006","volume":"40","author":"D-C Valla","year":"2016","unstructured":"Valla D-C. Dominique Cazals-Hatem. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2016;40(4):378\u201385. https:\/\/doi.org\/10.1016\/j.clinre.2016.01.006.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"965_CR45","doi-asserted-by":"publisher","first-page":"e00103","DOI":"10.14309\/crj.0000000000000103","volume":"6","author":"T Tariq","year":"2019","unstructured":"Tariq T, Dawdy J, Goyal S, Mohamad B, Singh M, Mutchnick M, et al. Hepatic sinusoidal obstruction syndrome in a patient with multiple myeloma treated with CyBorD. ACG Case Rep J. 2019;6(7):e00103. https:\/\/doi.org\/10.14309\/crj.0000000000000103.","journal-title":"ACG Case Rep J"},{"issue":"6","key":"965_CR46","doi-asserted-by":"publisher","first-page":"e26963","DOI":"10.1002\/pbc.26963","volume":"65","author":"M Mauro","year":"2018","unstructured":"Mauro M, Saggiorato G, Sartori MT, Gallo G, De Bortoli M, Bonetti E, et al. Venoocclusive disease due to chemotherapy for pediatric acute lymphoblastic leukemia is associated with increased levels of plasminogen-activator inhibitor-1. Pediatr Blood Cancer. 2018;65(6):e26963. https:\/\/doi.org\/10.1002\/pbc.26963.","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"965_CR47","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656\u201365. https:\/\/doi.org\/10.1182\/blood-2015-10-676924.","journal-title":"Blood"},{"issue":"9","key":"965_CR48","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/jcpt.13739","volume":"47","author":"R Jiang","year":"2022","unstructured":"Jiang R, Mei S, Zhao Z. Leucovorin (folinic acid) rescue for high-dose methotrexate: A review. J Clin Pharm Ther. 2022;47(9):1452\u201360. https:\/\/doi.org\/10.1111\/jcpt.13739.","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"965_CR49","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/hpb.12047","volume":"15","author":"C Hubert","year":"2013","unstructured":"Hubert C, Sempoux C, Humblet Y, van den Eynde M, Zech F, Leclercq I, et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford). 2013;15(11):858\u201364. https:\/\/doi.org\/10.1111\/hpb.12047.","journal-title":"HPB (Oxford)"},{"issue":"2","key":"965_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2165\/11319000-000000000-00000","volume":"33","author":"S Bailey","year":"2010","unstructured":"Bailey S, Singh A, Azadian R, Huber P, Blum M. Prospective data mining of six products in the US FDA adverse event reporting system: disposition of events identified and impact on product safety profiles. Drug Saf. 2010;33(2):139\u201346. https:\/\/doi.org\/10.2165\/11319000-000000000-00000.","journal-title":"Drug Saf"},{"issue":"5","key":"965_CR51","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2020.02.004","volume":"31","author":"E Charvet","year":"2020","unstructured":"Charvet E, Lheure C, Isnard C, Franck N, Kramkimel N, Vallet-Pichard A, et al. Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report. Ann Oncol. 2020;31(5):661\u20132. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.004.","journal-title":"Ann Oncol"},{"issue":"1","key":"965_CR52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.15403\/jgld-3207","volume":"30","author":"M Riveiro-Barciela","year":"2021","unstructured":"Riveiro-Barciela M, Gonzalez-Sans D, Marmolejo D, Salcedo MT, Munoz-Couselo E. Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. J Gastrointestin Liver Dis. 2021;30(1):171\u20132. https:\/\/doi.org\/10.15403\/jgld-3207.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"4","key":"965_CR53","doi-asserted-by":"publisher","first-page":"e1038","DOI":"10.14309\/crj.0000000000001038","volume":"10","author":"NY Sarsour","year":"2023","unstructured":"Sarsour NY, Minervini M, Malik SM. Cemiplimab-associated sinusoidal obstruction syndrome. ACG Case Rep J. 2023;10(4):e1038. https:\/\/doi.org\/10.14309\/crj.0000000000001038.","journal-title":"ACG Case Rep J"},{"issue":"3","key":"965_CR54","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2024.01.046","volume":"167","author":"Q Herms","year":"2024","unstructured":"Herms Q, Fuster-Anglada C, Juanola A. Pembrolizumab-induced liver injury: beyond immune-mediated hepatitis. Gastroenterology. 2024;167(3):443\u20135. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.046.","journal-title":"Gastroenterology"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00965-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:48:33Z","timestamp":1757252913000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00965-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00965-5","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}